Navigation Links
eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
Date:6/19/2008

PHILADELPHIA, June 19 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized ECG and eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device and related industries, announced today the availability of the EXPeRT(R) ePRO Suicidality Monitoring System(TM) (SMS). Suicidality screening is required in a growing number of drug development programs as a part of effective drug profiling and subject safety monitoring in clinical trials. The SMS was developed to address regulatory concerns and reduce the cost and time associated with clinician-administered suicidality assessments. It will also improve the quality of suicidality assessments compared to those performed by clinicians alone. SMS was developed in conjunction with Drs. John Greist, Alan Gelenberg, James Mundt, David Katzelnick and Jeff Jefferson. It is the most recent addition to a growing line of telephone-based assessments within the EXPeRT(R) ePRO services offered by eRT.

SMS is a simple patient monitoring and alert tool. It enhances subject comfort while generating critical information for site research staff and investigators in evaluating suicidality risk factors. It is easily added to any clinical trial. If a potential suicidality signal is detected for a subject, the SMS promptly alerts the investigator site to permit more in-depth clinical follow-up and evaluation.

Dr. John Greist, an eRT consultant with decades of experience and research on computer interviewing, described some of the benefits of SMS: "SMS provides a user-friendly telephone interface as a computer terminal to collect sensitive suicidality data directly from trial subjects. Advantages of Interactive Voice Response (IVR) technology are: constant availability; reliable, consistent, and complete presentation of every question; electronic recording of respondents' answers; documentation of the assessment completion; and prompt feedback and reporting to the study sites. Patients are more likely to disclose sensitive subject matter, including suicidality, in computer interviews than they will to human interviewers. The SMS models the ideal human interviewer, comprehensively and consistently covering every relevant topic while efficiently branching around irrelevant questions. Sound science requires standardization of measurement; the SMS provides a standard of procedural reliability that surpasses the reliability of human investigators performing such assessments."

"Just as the use of digital ECGs in assessing cardiac safety has become an essential part of drug development, we believe that the use of SMS in assessing suicidality will also become an integral part of the drug development process," said Jeffrey S. Litwin, M.D., eRT's Chief Medical Officer.

EXPeRT(R) ePRO was launched by eRT in conjunction with Healthcare Technology Systems (HTS), a leading authority in the research, development and validation of computer administered clinical rating instruments. It leverages HTS' expertise and eRT's existing infrastructure and role as a leading provider of clinical solutions to the pharmaceutical, biotechnology, medical device and related industries. Electronic patient reported outcome (ePRO) assessments are standardized, with all questions asked and scored by direct automated methods from trial subjects at any location with telephone access. Additionally, ePRO assessments provide subject response checking during interviews, offer immediate data storage to prevent potential data loss, and improve the accuracy and timeliness of subject data entry and increased clinical study efficiencies.

About eResearchTechnology, Inc.

Philadelphia-based eResearchTechnology (http://www.eRT.com) delivers technology-based products and services that enable pharmaceutical, biotechnological and medical device companies to collect, interpret and distribute cardiac safety and clinical data more efficiently. eRT is a market leader in centralized electrocardiographic (ECG) services-a core diagnostic capability-and a leading provider of technology and services that allow customers to automate and streamline data-based components of clinical trials, helping them bring new drugs to market faster.

Forward-looking statements

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including but not limited to 2008 financial guidance, involve a number of risks and uncertainties such as the company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
2. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
3. Oridion Announces Major Medical Research and Congress Presentations
4. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
5. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
6. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
7. Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
8. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
9. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. XTENT Announces European Regulatory Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017  GenomeDx Biosciences today announced that six ... Decipher® Prostate Cancer Classifier tests will be presented at ... (EAU) Congress held March 24 to 28, 2017 in ... Congress is Europe,s largest urological ... the urological field. The abstract titled "Muscle ...
(Date:3/24/2017)... DALLAS , March 23, 2017  HealthMine surveys ... January 2017 revealed that health plan members want help ... reason to stay engaged in their health, 2) help ... an integrated platform for health and 5) relevant, real-time ... outcomes and lowering healthcare costs. ...
(Date:3/24/2017)... 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today disclosed terms ... Sheet (the "Definitive Financing") it entered into on ... stockholders, who are referred to in the Definitive ... filed with the Securities and Exchange Commission.   ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... 2017 , ... According to the American Cancer Society , the average ... 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, the ... avoid this latter group, tune in to Lifestyle Magazine on April 9, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... agreement to resolve the pending litigation between itself and 1800 Vending DBA Healthy ... Utah). , “I am thrilled to announce that we have now reached a ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider of ... products to the Deaf Seniors of America Conference, April 4-7 at the Hotel Westin ... knowledgeable ASL friendly staff from Harris Communications and to try out the newest assistive ...
(Date:3/24/2017)... Hatboro, Pennsylvania (PRWEB) , ... March 24, 2017 ... ... and recycling solutions for contaminated soil, dredged material, and hazardous and non-hazardous materials ... headquartered in Allentown, Pennsylvania. This acquisition will add four additional processing facilities ...
(Date:3/24/2017)... ... , ... Digital Scientists, a software innovation lab specializing in web design and ... South Carolina location. The lab has set up shop at the renowned NEXT ... South Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ ...
Breaking Medicine News(10 mins):